Logo

CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

Share this

CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

Shots:

  • Black Belt to get $5.64M (€5M) upfront- equity investment of $2.26M (€2M)- milestones and royalties on sales. CASI to get exclusive WW rights to develop and commercialize Black Belt’s anti-CD38 monoclonal antibody (Mab) TSK011010 program
  • The equity investment of $2.26M will be in a newly built subsidiary of Black Belt focusing on novel immuno-oncology targets
  • Anti-CD38 Mab program TSK011010 is an IgG1 mAb developed to activate effector T cells and NK cells and will be evaluated in P-I with expected onset in H2’19 or H1’20

Ref: Casi Pharmaceuticals | Image: Casi Pharmaceuticals

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions